Bluejay Diagnostics IncBJDX
▲ PositiveCapitalrelevance
Strengthened balance sheet with increased cash and financing proceeds.
Impact on stocks 1
Biotech & Genomic Medicine
Bluejay Diagnostics IncBluejay Diagnostics reported its second quarter 2026 results, highlighting a strengthened balance sheet. At June 30, 2026, the company had approximately $9.6 million in cash and cash equivalents, up from approximately $5.2 million at December 31, 2025. During the first six months of 2026, Bluejay generated approximately $7.7 million of net cash from financing activities, including approximately $7.6 million of net proceeds from its June 2026 private placement.
Bluejay Diagnostics IncStrengthened balance sheet with increased cash and financing proceeds.